Connetics' investigational acne drug Velac—a once-a-day mixture of topical clindamycin and tretinoin in hydrogel—may be more convenient and at least as safe as either workhorse acne agent alone, say new studies. The findings could be hopeful news for the estimated 17 million or more Americans with acne. These results were reported at the American Academy of Dermatology annual meeting in New Orleans last month.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.